Feb 7 2012
Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.
"This accelerating growth continues to send a strong signal that the market is embracing the Spectros broadband tissue oximetry," notes CFO John Bagnatori.
Spectros T-Stat® is the only broadband tissue oximeter on the market in the U.S., Europe, and Asia. T-Stat's proprietary broadband oximetry relies on over 260 wavelengths of light, compared just 2-4 wavelengths used in other oximeters. T-Stat competes with INVOS® oximeters marketed by Covidien, and FORE-SIGHT® oximeters marketed by CAS Medical. In reconstructive surgery, T-Stat competes with oximeters marketed by ViOptix.
An expanded array of products, including broadband infrared Ceres™ cerebral probes and multi-site T-Stat monitors are under development.